Skip to main content
. 2017 Oct 13;12(10):e0185563. doi: 10.1371/journal.pone.0185563

Table 1. Association between expression of HSP10 and c-PARP proteins and astrocytoma clinical pathological features (n = 103).

Characteristics (n) HSP10 c-PARP HSP10/c-PARP#
Low (%) High (%) P-value Low (%) High (%) P-value N- (%) P+ (%) P-value
Age1
< 43 (n = 44) 28(63.6) 16(36.4) 0.431 31(70.5) 13(29.5) 0.642 34 (77.3) 10 (22.7) 0.055
≥43 (n = 59) 33(55.9) 26(44.1) 44(74.6) 15(25.4) 35(59.3) 24 (40.7)
Gender
Female (n = 54) 33 (61.1) 21(38.9) 0.682 36 (66.7) 18 (33.3) 0.141 37 (68.5) 17 (31.5) 0.729
Male (n = 49) 28 (57.1) 21(42.9) 39(79.6) 10 (20.4) 32(65.3) 17(34.7)
Tumor size2
<5.0 cm (n = 58) 30 (51.7) 28 (48.3) 0.079 47 (81.0) 11 (19.0) 0.033* 35 (60.3) 23(39.7) 0.103
≥5.0 cm (n = 45) 31(68.9) 14(31.1) 28(62.2) 17 (37.8) 34(75.6) 11 (24.4)
WHO grade
I (n = 16) 11 (68.8) 5(31.2) 13 (81.3) 3 (18.7) 11 (68.8) 5 (31.2)
II(n = 32) 21 (65.6) 11 (34.4) 28 (87.5) 4 (12.5) 19 (59.4) 13(40.6)
III(n = 39) 23 (59.0) 16 (41.0) 0.234 26 (66.7) 13 (33.3) 0.029* 28 (71.8) 11(28.2) 0.731
IV (n = 16) 6 (37.5) 10 (62.5) 8(50.0) 8 (50.0) 11(68.8) 5 (31.2)
Survival status
Replase free survival (n = 36) 27 (75.0) 9 (25.0) 29(80.6) 7 (19.4) 30(83.3) 6 (16.7)
Replase (n = 25) 10 (40.0) 15 (60.0) 0.022* 15(60.0) 10 (40.0) 0.203 13(52.0) 12 (48.0) 0.025*
Death (n = 42) 24 (57.1) 18 (42.9) 31(73.8) 11 (26.2) 26(61.9) 16 (38.1)

Abbreviations: Statistical analysis was performed using the Chi-squared test.

*Statistically significant (p < 0.05).

1The average age of all subjects was 42.3 years;

2The average tumor size of all subjects was 5.0cm. n, Number of cases; WHO, World Health Organization.

# N-: Other immunophenotype of HSP10 and c-PARP; P+: High expression of HSP10 and low expression of c-PARP.